Dr. Glynn Wilson the Chairman and CEO of TapImmune will present at the Sachs Associates' 3rd Annual Bio Partnering & Investment Forum on 2/23. The company had Phase I trials completed with 20 of 21 cancer patients reacting with positive immune responses. Additionally, TapImmune has a very deep drug pipeline in multipe indications for upcoming Phase II trials....